Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease
Diabetes2008Vol. 58(2), pp. 318–328
Citations Over TimeTop 10% of 2008 papers
Bronwen Martin, Erin Golden, Olga D. Carlson, Paul J. Pistell, Jie Zhou, Wook Kim, Brittany P. Frank, Sam Thomas, Wayne Chadwick, Nigel H. Greig, Gillian P. Bates, Kirupa Sathasivam, Michel Bernier, Stuart Maudsley, Mark P. Mattson, Josephine M. Egan
Abstract
Targeting both peripheral and neuronal deficits, Ex-4 is an attractive agent for therapeutic intervention in Huntington's disease patients suffering from diabetes.
Related Papers
- → Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington’s disease(2007)112 cited
- → Impaired mitochondrial trafficking in Huntington's disease(2009)67 cited
- → Recent Trends in Detection of Huntingtin and Preclinical Models of Huntington’s Disease(2014)5 cited
- → Inhibition of caspase-6: A potential therapy for Huntington’s disease(2008)
- Assessments of potential interactions of huntingtin-associated-protein-1 in the R6/2 mouse model of Huntington's disease(2004)